Advertisement

Topics

Fitch stuft Astrazeneca auf BBB+ ab

13:30 EDT 12 Oct 2018 | FinanzNachrichten

FRANKFURT (Dow Jones)--Fitch hat die Bonität des Pharmakonzerns Astrazeneca heruntergestuft. Das langfristige Emittentenausfallrating wurde auf BBB+ von A- gesenkt, teilte die Ratingagentur mit. D...

Original Article: Fitch stuft Astrazeneca auf BBB+ ab

NEXT ARTICLE

More From BioPortfolio on "Fitch stuft Astrazeneca auf BBB+ ab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...